{"analyses":[{"ciLowerLimit":"-0.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.27","groupDescription":"PFS Rate at 6 months","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0593","paramType":"Difference in Event Free Rate","paramValue":"8.47","statisticalMethod":"Z-test"},{"ciLowerLimit":"1.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.02","groupDescription":"PFS Rate at 1 year","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0133","paramType":"Difference in Event Free Rate","paramValue":"7.27","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.56","upperLimit":"28.22","value":"22.39"},{"groupId":"OG001","lowerLimit":"24.26","upperLimit":"37.45","value":"30.86"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.14","upperLimit":"8.56","value":"5.35"},{"groupId":"OG001","lowerLimit":"7.85","upperLimit":"17.40","value":"12.62"}]}],"title":"1 Year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"PFS rates at 6 months and at 1 year is defined as the proportion of participants who are alive without disease progression 6 months and 1 year after randomization, respectively.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Placebo + Carboplatin + Etoposide"},{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG001","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"NUMBER","populationDescription":"The ITT population was defined as all randomized participants, regardless of whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"6 months, 1 year","title":"PFS Rate at 6 Months and at 1 Year in Global Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}